FDA: Mifepristone review won’t be done until March
Summary
The Food and Drug Administration (FDA) said it will not complete its safety review of the abortion pill mifepristone until March. The FDA also said it will not add new limits on using the drug before finishing the review.Key Facts
- The FDA filed a court document on Wednesday about mifepristone.
- The safety review of the abortion medication mifepristone will not be finished until March.
- No new restrictions on mifepristone will be put in place before the review is done.
- The announcement may upset people who oppose abortion and want tighter controls.
- Mifepristone is a drug used to end early pregnancies.
- The FDA regulates the safety and use of drugs in the U.S.
Read the Full Article
This is a fact-based summary from The Actual News. Click below to read the complete story directly from the original source.
